Unapproved stem cell therapies remains a top FDA enforcement priority | Hogan Lovells
Speaking Tuesday at the Food and Drug Law Institute (FDLI) Annual Conference, Mark Raza, FDA Chief Counsel, discussed the investigations priorities for FDA’s Office of the Chief Counsel...
Source: jdsupra.com